1. Hortobagyi, GN, de la Garza Salazar, J, Pritchard, K, et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer. 2005;6:391-401. doi:10.3816/CBC.2005.n.043.
Google Scholar | Crossref | Medline2. Trivers, KF, Lund, MJ, Porter, PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009;20:1071-1082.
Google Scholar | Crossref | Medline | ISI3. Thike, AA, Yong-Zheng Chong, L, Cheok, PY, et al. Loss of androgen receptor expression predicts early recurrence in triple negative and basal-like breast cancer. Mod Pathol. 2013;27:352-360. doi:10.1038/modpathol.2013.145.
Google Scholar | Crossref | Medline4. Kumar, P, Aggarwal, R. An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2016;293:247-269. doi:10.1007/s00404-015-3859-y.
Google Scholar | Crossref | Medline5. Polk, A, Svane, IM, Andersson, M, Nielsen, D. Checkpoint inhibitors in breast cancer – current status. Cancer Treat Rev. 2018;63:122-134. doi:10.1016/j.ctrv.2017.12.008.
Google Scholar | Crossref | Medline6. Scholzen, T, Gerdes, J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311-322. doi:10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9.
Google Scholar | Crossref | Medline | ISI7. Tan, AS, Yeong, JP, Lai, CP, et al. The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach. Virchows Arch. 2019;475:709-725. doi:10.1007/s00428-019-02635-4.
Google Scholar | Crossref | Medline8. Wu, Q, Ma, G, Deng, Y, et al. Prognostic value of Ki-67 in patients with resected triple-negative breast cancer: a meta-analysis. Front Oncol. 2019;9:1068. doi:10.3389/fonc.2019.01068.
Google Scholar | Crossref | Medline9. Keam, B, Im, SA, Lee, KH, et al. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res. 2011;13:R22.
Google Scholar | Crossref | Medline | ISI10. Li, XR, Liu, M, Zhang, YJ, et al. CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Med Oncol. 2011;28:S129-S134.
Google Scholar | Crossref | Medline | ISI11. Scholl, SM, Pierga, JY, Asselain, B, et al. Breast tumor response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer. 1995;31A:1969-1975.
Google Scholar | Crossref | Medline | ISI12. Kuerer, HM, Newman, LA, Smith, TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460-469.
Google Scholar | Crossref | Medline | ISI13. Jeong, H, Ryu, YJ, An, J, Lee, Y, Kim, A. Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype. Histopathology. 2012;60:E87-E95. doi:10.1111/j.1365-2559.2012.04195.x.
Google Scholar | Crossref | Medline14. Yamashita, N, Tokunaga, E, Kitao, H, et al. Vimentin as a poor prognostic factor for triple-negative breast cancer. J Cancer Res Clin Oncol. 2013;139:739-746.
Google Scholar | Crossref | Medline | ISI15. Savci-Heijink, CD, Halfwerk, H, Hooijer, GKJ, et al. Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior. Breast Cancer Res Treat. 2019;174:649-659. doi:10.1007/s10549-018-05089-5.
Google Scholar | Crossref | Medline16. Lakhani, SR, Ellis, IO, Schnitt, SJ, Tan, PH, Vijver, MJ. WHO Classification of Tumours of the Breast. 4th ed. Lyon, France: IARC Press; 2012.
Google Scholar17. Edge, SB, Byrd, DR, Compton, CC, Fritz, AG, Greene, FL, Trotti, A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
Google Scholar18. Dowsett, M, Nielsen, TO, A’Hern, R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011;103:1656-1664.
Google Scholar | Crossref | Medline19. von Minckwitz, G, Untch, M, Blohmer, JU. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796-1804. doi:10.1200/JCO.2011.38.8595.
Google Scholar | Crossref | Medline | ISI20. Zhu, X, Chen, L, Huang, B, et al. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci Rep. 2020;10:225. doi:10.1038/s41598-019-57094-3.
Google Scholar | Crossref | Medline21. Hao, S, He, Z, Yu, K, Yang, WT, Shao, ZM. New insights into the prognostic value of KI 67 labelling index in patients with triple-negative breast cancer. Oncotarget. 2016;7:24824-24831.
Google Scholar | Crossref | Medline22. Petrelli, F, Viale, G, Cabiddu, M, Barni, S. Prognostic value of different cut-off levels of KI 67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat. 2015;153:477-491.
Google Scholar | Crossref | Medline23. Aleskandarany, MA, Green, AR, Benhasouna, AA, et al. Prognostic value of proliferation assay in the luminal, HER2 positive and triple negative biological classes of breast cancer. Breast Cancer Res. 2012;14:R319.
Google Scholar | Crossref | Medline24. Miyashita, M, Ishida, T, Ishida, K, et al. Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates. Virchows Arch. 2011;458:65-72. doi:10.1007/s00428-010-1009-2.
Google Scholar | Crossref | Medline25. Wang, W, Wu, J, Zhang, P, et al. Prognostic and predictive value of Ki-67 in triple-negative breast cancer. Oncotarget. 2016;7:31079-31087. www.impactjournals.com/oncotarget/
Google Scholar26. Nishimura, R, Osako, T, Okumura, Y, Hayashi, M, Arima, N. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer. 2010;17:269-275. doi:10.1007/s12282-009.
Google Scholar | Crossref | Medline | ISI27. Petit, T, Wilt, M, Velten, M, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004;40:205-211.
Google Scholar | Crossref | Medline28. Mauriac, L, MacGrogan, G, Avril, A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Ann Oncol. 1999;10:47-52.
Google Scholar | Crossref | Medline | ISI29. Jones, RL, Salter, J, A’Hern, R, et al. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2010;119:315-323.
Google Scholar | Crossref | Medline | ISI30. Burcombe, RJ, Makris, A, Richman, PI, et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer. 2005;92:147-155.
Google Scholar | Crossref | Medline | ISI31. Colleoni, M, Viale, G, Zahrieh, D, et al. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol. 2008;19:465-472.
Google Scholar | Crossref | Medline32. Faneyte, IF, Schrama, JG, Peterse, JL, Remijnse, PL, Rodenhuis, S, van de Vijver, MJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer. 2003;88:406-412.
Google Scholar | Crossref | Medline | ISI33. von Minckwitz, G, Sinn, HP, Raab, G, et al. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res. 2008;10:R30.
Google Scholar | Crossref | Medline | ISI34. Jones, RL, Salter, J, A’Hern, R, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009;116:53-68.
Google Scholar | Crossref | Medline35. Lee, J, Im, YH, Lee, SH, et al. Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Cancer Chemother Pharmacol. 2008;61:569-577.
Google Scholar | Crossref | Medline | ISI36. Niikura, N, Sakatani, T, Arima, N, et al. Assessment of the Ki67 labeling index: a Japanese validation ring study. Breast Cancer. 2016;23:92-100.
Google Scholar | Crossref | Medline37. Munzone, E, Botteri, E, Sciandivasci, A, et al. Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. Breast Cancer Res Treat. 2012;134:277-282. doi:10.1007/s10549-012-2040-6.
Google Scholar | Crossref | Medline38. Mrklić, I, Ćapkun, V, Pogorelić, Z, Tomić, S. Prognostic value of Ki-67 proliferating index in triple negative breast carcinomas. Pathol Res Pract. 2013;209:296-301. doi:10.1016/j.prp.2013.02.012.
Google Scholar | Crossref | Medline39. Yerushalmi, R, Woods, R, Ravdin, PM, Hayes, MM, Gelmon, KA. Ki-67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11:174-183. doi:10.1016/S1470-204570262-1.
Google Scholar | Crossref | Medline | ISI